3 of the Best ETFs to Buy and Hold if a Recession Is Coming

The article recommends three ETFs as defensive investments during an anticipated recession: Vanguard Healthcare ETF (VHT) for exposure to non-cyclical healthcare stocks, Vanguard Total Bond Market ETF (BND) to benefit from expected interest rate cuts, and Vanguard S&P 500 ETF (VOO) for long-term growth despite near-term volatility. Historical data shows the S&P 500 has delivered 10% annual returns despite recessions, suggesting buy-and-hold strategies outperform panic selling.

10/02/2026, 1:05 PM • The Motley Fool

Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory.

10/02/2026, 12:15 PM • The Motley Fool

Prediction: This Stock Could Double Over the Next 5 Years

Viking Therapeutics' weight loss drug VK2735 shows strong clinical promise with potential for dual-formulation therapy (injectable followed by oral maintenance). The company raised $500 million to fund pipeline development. With the obesity drug market projected to reach $77 billion by 2030, even a small 1.4% market share could generate $1.2 billion in revenue for Viking's $4 billion market cap, suggesting significant upside potential, though clinical trial risks remain.

10/02/2026, 6:15 AM • The Motley Fool

Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market.

Eli Lilly's phase three trial results for retatrutide (TRIUMPH-2) show strong weight loss outcomes, with 59.5% of participants no longer classified as obese and over half losing 20% of body weight. The triple agonist drug also reduced blood sugar levels and showed additional benefits for arthritis pain and sleep apnea. Retatrutide appears to outperform competing weight-loss drugs like tirzepatide, Wegovy, and Ozempic. Lilly plans to submit a biologics license application to the FDA in Q1 2027.

09/30/2026, 12:04 PM • The Motley Fool

Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?

Roche's weight loss drug candidate enicepatide has shown promising Phase 2 results with 22.5% mean weight loss over 48 weeks, potentially competing with Eli Lilly's Zepbound and Novo Nordisk's semaglutide. However, while enicepatide demonstrates competitive efficacy, Roche is unlikely to overtake the market leaders due to their deeper pipelines. Roche remains a solid investment opportunity with diversified healthcare products and consistent growth prospects.

09/30/2026, 10:24 AM • The Motley Fool

Meet the Low-Cost Vanguard ETF With 51.8% Invested in Nvidia, Apple, Alphabet, Microsoft, and Amazon While VOO Has Just 30%

The Vanguard Morningstar Mega Cap Growth ETF (MGK) offers concentrated exposure to mega-cap growth stocks, with 51.8% invested in Nvidia, Apple, Alphabet, Microsoft, and Amazon compared to 30% for the S&P 500 ETF (VOO). While MGK has a slightly higher expense ratio (0.05% vs 0.03%), it provides amplified exposure to AI-driven growth opportunities. However, this concentration carries risks if mega-cap growth stocks underperform, though the article argues these companies are well-positioned to capitalize on AI investments at scale.

09/30/2026, 7:30 AM • The Motley Fool

Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

09/30/2026, 4:58 AM • GlobeNewswire

3 Undervalued Healthcare Stocks Invstors Can Buy Right Now

The healthcare industry is being overlooked by investors who are primarily focused on artificial intelligence. Healthcare stocks offer relatively stable consumer spending compared to most other industries, presenting potential buying opportunities.

09/29/2026, 11:35 PM • The Motley Fool

Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two pharmaceutical giants with divergent strategies: Bristol Myers Squibb, a deep-value dividend payer trading at cheap multiples (P/E 14.07) with flat revenue but stabilizing earnings, versus Eli Lilly, a high-growth juggernaut riding explosive success in GLP-1 metabolic drugs with 45% revenue growth and a P/E of 40.26. Despite BMY's attractive valuation, the author recommends LLY for 2026 due to its strong growth trajectory, successful drug pipeline including Retatrutide and lipoprotein(a) therapeutics, and forecast for 30% revenue growth.

09/29/2026, 6:22 PM • The Motley Fool

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

Viking Therapeutics released impressive clinical trial results for its weight-loss drug VK2735, showing 16-19% body weight loss and strong maintenance results. However, Eli Lilly's stock barely moved because the company has its own robust maintenance strategies (Foundayo and dose reduction approaches) and a deeper pipeline. While Viking could become a competitor in the growing weight-loss market, it still needs to confirm results in larger Phase 3 trials, and Eli Lilly remains the safer, more established choice.

09/29/2026, 5:30 PM • The Motley Fool

Want a $1 Million Investment Portfolio? History Says This Strategy Could Get You There.

The article outlines how everyday investors can build a $1 million portfolio through dollar-cost averaging and consistent S&P 500 investing. By investing $500-$2,000 monthly over 18-31 years, investors can reach millionaire status, with compound returns doing most of the heavy lifting. The S&P 500 has historically averaged 10.6% annual returns and outperforms 84% of actively managed funds, making it a reliable wealth-building strategy.

09/29/2026, 2:15 AM • The Motley Fool

2 of the Best ETFs to Buy When Inflation Is Running Hot

With inflation rising to 3.4% in August and potentially climbing further, two actively managed ETFs are positioned to outperform during inflationary periods: the Avantis Inflation Focused ETF (AVIE), which invests in inflation-correlated sectors like energy and healthcare, and the VanEck Real Assets ETF (RAAX), which focuses on commodities and real assets. Both have demonstrated strong performance when inflation spikes, though they underperform during bull markets.

09/28/2026, 10:27 AM • The Motley Fool

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

Viking Therapeutics' GLP-1 drug VK2735 showed promising clinical trial results with 16-19% weight loss and strong maintenance rates, causing the stock to surge. While riskier than Eli Lilly due to its smaller $4.1B market cap and lack of approved drugs, Viking could offer significant upside potential through drug approval or acquisition by a larger healthcare company.

09/28/2026, 9:01 AM • The Motley Fool

Here's Where Wall Street Analysts See Eli Lilly's Share Price Going

Eli Lilly's stock has underperformed the broader market in 2026 despite a strong 5-year run, trading at 40x earnings. Wall Street analysts are modestly bullish with an average price target of $1,325 (11% upside), with 25 of 30 analysts recommending buy. The expanding GLP-1 market, projected to reach $190 billion by 2045, and Lilly's strong patent protection through the late 2030s support a positive outlook despite competitive threats from Novo Nordisk.

09/26/2026, 12:32 PM • The Motley Fool

Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become

Eli Lilly discontinued development of a new GLP-1 weight-loss drug that failed to meet efficacy expectations. While GLP-1 drugs (Mounjaro, Zepbound, Foundayo) account for over 65% of the company's revenue, Eli Lilly is strategically preparing for future patent expirations by aggressively investing in its drug pipeline through acquisitions and in-house research, particularly in infectious diseases. The company's willingness to cut underperforming candidates and move quickly on acquisitions demonstrates strong long-term strategic positioning.

09/26/2026, 12:15 PM • The Motley Fool